ACT GRO 777

Drug Profile

ACT GRO 777

Alternative Names: ACT-GRO-777; AGRO-100; AS1411

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Alabama; University of Louisville
  • Developer Advanced Cancer Therapeutics; James Graham Brown Cancer Center
  • Class Antineoplastics; Nucleotide aptamers; Oligodeoxyribonucleotides
  • Mechanism of Action Apoptosis stimulants; Nucleolin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Acute myeloid leukaemia; Renal cell carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cancer
  • No development reported Neuroblastoma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neuroblastoma in USA (IV)
  • 03 May 2011 Preclinical trials in Neuroblastoma in USA (IV)
  • 28 Apr 2011 Advanced Cancer Therapeutics acquires ACT GRO 777 from Antisoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top